ERBB2 and neoplasm: Vaccines targeting Her2 represent a valid alternative to the use of anti-Her2 mAbs, as they can induce a long-lasting immune memory that may be able to overcome inherent primary or acquired tumor resistance mechanisms, which occur in a significant proportion of patients receiving trastuzumab and pertuzumab [12].